AR062584A1 - Medicamentos para tratar enfermedades de las vias respiratorias - Google Patents
Medicamentos para tratar enfermedades de las vias respiratoriasInfo
- Publication number
- AR062584A1 AR062584A1 ARP070103833A ARP070103833A AR062584A1 AR 062584 A1 AR062584 A1 AR 062584A1 AR P070103833 A ARP070103833 A AR P070103833A AR P070103833 A ARP070103833 A AR P070103833A AR 062584 A1 AR062584 A1 AR 062584A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- medications
- fenantren
- dodecahydro
- sulfanyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 2
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 abstract 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 abstract 2
- 239000003246 corticosteroid Substances 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- ZGWGSEUMABQEMD-UHFFFAOYSA-N 4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC=1N=CSC=1C(O)=O ZGWGSEUMABQEMD-UHFFFAOYSA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- 208000027771 Obstructive airways disease Diseases 0.000 abstract 1
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 229960000289 fluticasone propionate Drugs 0.000 abstract 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 1
- 229960002848 formoterol Drugs 0.000 abstract 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N pyromucic acid Natural products OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004017 salmeterol Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Medicamentos que comprenden (A) un agente anti-muscarínico, (B) un agonista del adreno-receptor beta-2, y (C) un corticosteroide, para el tratamiento de enfermedades inflamatorias u obstructivas de las vías respiratorias. Reivindicacion 1: Un medicamento, el cual comprende, por separado o juntos: (A) una sal de glicopirronio; (B) un agonista del adreno-receptor beta-2 seleccionado a partir de salmeterol y formoterol, o sales farmacéuticamente aceptables del mismo; y (C) un corticosteroide seleccionado a partir de propionato de fluticasona, (6S,9R,10S,11S,13S,16R,17R)-6,9-difluoro-17-fluoro- metil-sulfanil-carbonil-11-hidroxi-10,13,16-trimetil-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahidro-3H-ciclopenta-[a]- fenantren-17-iI-éster del ácido 4-metil-tiazol-5-carboxílico, (6S,9R,10S,11S,13S,16R,17R)-6,9-difluoro-17-fluoro-metil-sulfanil-carbonil-11-hidroxi-10,13,16-trimetil-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17- dodecahidro-3H-ciclopenta-[a]-fenantren-17- il-éster del ácido furan-2-carboxílico, y budesonida; para su administracion simultánea, en secuencia, o separada, en el tratamiento de una enfermedad inflamatoria u obstructiva de las vías respiratorias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06119917A EP1894568A1 (en) | 2006-08-31 | 2006-08-31 | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062584A1 true AR062584A1 (es) | 2008-11-19 |
Family
ID=37728252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103833A AR062584A1 (es) | 2006-08-31 | 2007-08-29 | Medicamentos para tratar enfermedades de las vias respiratorias |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100166671A1 (es) |
| EP (2) | EP1894568A1 (es) |
| JP (1) | JP2010501627A (es) |
| KR (1) | KR20090043540A (es) |
| CN (1) | CN101505761A (es) |
| AR (1) | AR062584A1 (es) |
| AU (1) | AU2007291241A1 (es) |
| BR (1) | BRPI0716215A2 (es) |
| CA (1) | CA2659339A1 (es) |
| CL (1) | CL2007002526A1 (es) |
| MX (1) | MX2009002307A (es) |
| PE (1) | PE20080924A1 (es) |
| RU (1) | RU2009111388A (es) |
| TW (1) | TW200816993A (es) |
| WO (1) | WO2008025787A2 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2330047T3 (es) * | 2005-12-21 | 2009-12-03 | MEDA PHARMA GMBH & CO. KG | Combinacion de r,r-glicopirrolato, rolipram y budesonida para el tratmiento de enfermedades inflamatorias. |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| GB0808708D0 (en) * | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
| BRPI0822693A2 (pt) | 2008-05-13 | 2015-07-07 | Astrazeneca Ab | Derivados de quinuclidina como antagonistas do receptor muscarínico m3 |
| KR20120015334A (ko) * | 2009-05-29 | 2012-02-21 | 펄 테라퓨틱스 인코포레이티드 | 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| AU2015201864A1 (en) * | 2009-05-29 | 2015-04-30 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems |
| AU2015201037C1 (en) * | 2009-05-29 | 2017-07-27 | Pearl Therapeutics, Inc. | Respiratory delivery of active agents |
| WO2010144628A2 (en) * | 2009-06-09 | 2010-12-16 | Elevation Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| AU2009100698B4 (en) * | 2009-07-17 | 2010-04-15 | Astrazeneca Ab | Combination |
| WO2011081937A1 (en) * | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
| PE20121396A1 (es) * | 2009-12-23 | 2012-10-24 | Chiesi Farma Spa | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol |
| PE20121467A1 (es) | 2009-12-23 | 2012-11-07 | Chiesi Farma Spa | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica |
| BR112012015334A2 (pt) * | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| UY33373A (es) | 2010-05-10 | 2011-12-30 | Gilead Sciences Inc | ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?. |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| CA2802584C (en) * | 2010-06-14 | 2018-08-21 | Chiesi Farmaceutici S.P.A. | Crystal form of glycopyrronium chloride |
| JP2014505717A (ja) | 2011-02-17 | 2014-03-06 | シプラ・リミテッド | 医薬組成物 |
| JO3510B1 (ar) | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
| CN105106200A (zh) * | 2011-05-17 | 2015-12-02 | 珍珠治疗公司 | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| RU2494730C1 (ru) * | 2012-03-27 | 2013-10-10 | Шолекс Девелопмент Гмбх | Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения |
| US10111957B2 (en) | 2012-07-05 | 2018-10-30 | Arven Ilac Snayi ve Ticaret A.S. | Inhalation compositions comprising glucose anhydrous |
| WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
| US20150202148A1 (en) | 2012-07-05 | 2015-07-23 | Arven llac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
| EA201590030A1 (ru) * | 2012-07-05 | 2015-09-30 | Арвен Айлак Санайи Ве Тиджарет А.С. | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент |
| EA036153B1 (ru) * | 2012-07-05 | 2020-10-06 | Арвен Айлак Санайи Ве Тиджарет А.С. | Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор |
| CN105142673B8 (zh) | 2012-12-18 | 2018-02-16 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物 |
| EA201591415A1 (ru) | 2013-01-31 | 2016-01-29 | Просоникс Лимитед | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| KR102377252B1 (ko) | 2013-02-28 | 2022-03-22 | 저니 메디컬 코퍼레이션 | 글리코피롤레이트 염 |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| EP2968152B2 (en) | 2013-03-15 | 2022-06-22 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| MA50680A (fr) | 2014-09-09 | 2020-08-05 | Vectura Ltd | Formulation comprenant glycopyrrolate, procédé et appareil |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TR201712424A2 (tr) * | 2017-08-21 | 2019-03-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Kuru toz i̇nhalasyon bi̇leşi̇mleri̇ |
| WO2020229966A1 (en) * | 2019-05-10 | 2020-11-19 | Glenmark Pharmaceutical Limited | Stable aerosol composition for inhalation comprising glycopyrronium |
| CN117679423A (zh) | 2022-09-05 | 2024-03-12 | 立生医药(苏州)有限公司 | 预防或治疗呼吸系统疾病的吸入用药物组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| GB0124523D0 (en) * | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
| GB0207906D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| AU2004311478A1 (en) * | 2003-12-31 | 2005-07-21 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| WO2005074982A2 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| GB0415789D0 (en) * | 2004-07-15 | 2004-08-18 | Astrazeneca Ab | Novel combination |
| GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| DE102004056579A1 (de) * | 2004-11-23 | 2006-05-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Salmeterol und ein Steroid |
| US20070098644A1 (en) * | 2005-10-31 | 2007-05-03 | Richie's Pharmacy And Medical Supply, Incorporated | Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease |
| ES2330047T3 (es) * | 2005-12-21 | 2009-12-03 | MEDA PHARMA GMBH & CO. KG | Combinacion de r,r-glicopirrolato, rolipram y budesonida para el tratmiento de enfermedades inflamatorias. |
-
2006
- 2006-08-31 EP EP06119917A patent/EP1894568A1/en not_active Ceased
-
2007
- 2007-08-29 AU AU2007291241A patent/AU2007291241A1/en not_active Abandoned
- 2007-08-29 US US12/377,630 patent/US20100166671A1/en not_active Abandoned
- 2007-08-29 WO PCT/EP2007/058972 patent/WO2008025787A2/en not_active Ceased
- 2007-08-29 PE PE2007001172A patent/PE20080924A1/es not_active Application Discontinuation
- 2007-08-29 CA CA002659339A patent/CA2659339A1/en not_active Abandoned
- 2007-08-29 CN CNA2007800303799A patent/CN101505761A/zh active Pending
- 2007-08-29 BR BRPI0716215-4A patent/BRPI0716215A2/pt not_active Application Discontinuation
- 2007-08-29 KR KR1020097004156A patent/KR20090043540A/ko not_active Withdrawn
- 2007-08-29 RU RU2009111388/15A patent/RU2009111388A/ru unknown
- 2007-08-29 JP JP2009526092A patent/JP2010501627A/ja active Pending
- 2007-08-29 EP EP07802989A patent/EP2059249A2/en not_active Withdrawn
- 2007-08-29 MX MX2009002307A patent/MX2009002307A/es not_active Application Discontinuation
- 2007-08-29 AR ARP070103833A patent/AR062584A1/es unknown
- 2007-08-30 TW TW096132312A patent/TW200816993A/zh unknown
- 2007-08-30 CL CL200702526A patent/CL2007002526A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101505761A (zh) | 2009-08-12 |
| CL2007002526A1 (es) | 2008-07-11 |
| WO2008025787A2 (en) | 2008-03-06 |
| MX2009002307A (es) | 2009-03-20 |
| TW200816993A (en) | 2008-04-16 |
| RU2009111388A (ru) | 2010-10-10 |
| JP2010501627A (ja) | 2010-01-21 |
| CA2659339A1 (en) | 2008-03-06 |
| PE20080924A1 (es) | 2008-08-29 |
| EP2059249A2 (en) | 2009-05-20 |
| EP1894568A1 (en) | 2008-03-05 |
| BRPI0716215A2 (pt) | 2013-10-15 |
| AU2007291241A1 (en) | 2008-03-06 |
| KR20090043540A (ko) | 2009-05-06 |
| US20100166671A1 (en) | 2010-07-01 |
| WO2008025787A3 (en) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062584A1 (es) | Medicamentos para tratar enfermedades de las vias respiratorias | |
| ES2493641T3 (es) | Administración nasal de soluciones acuosas de corticosteroides | |
| US20180235931A1 (en) | Use of neurokinin-1 antagonists as antitussives | |
| CL2004001170A1 (es) | Combinacion farmaceutica inhalable que contiene (a) formoterol, o una sal, o un solvato de el o de la sal y (b) furoato de mometasona; estuche farmaceutico que la comprende; y su uso en la terapia de una enfermedad inflamatoria u obstructiva de las v | |
| JP2015524444A5 (es) | ||
| CO5140098A1 (es) | Combinaciones de un agonista de betra-2 y un esteroide, su uso para tratamiento de enfermedades inflamatorias u obstructivas de las vias aereas | |
| EP3478283A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
| JP2010132695A5 (es) | ||
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| BRPI0719115B8 (pt) | sistema terapêutico transdérmico para administração de buprenorfina à pele | |
| JP2007536311A5 (es) | ||
| WO2008040534A3 (en) | Non-mucoadhesive film dosage forms | |
| PE20081788A1 (es) | Combinaciones farmaceuticas | |
| EP2364144A4 (en) | GALENIC FORM FOR INSERTION IN THE MOUTH | |
| JP2007314517A5 (es) | ||
| AR058194A1 (es) | Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide | |
| JP2013503150A (ja) | Ｉｂｄ治療のための医薬組成物 | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| JP2016518388A5 (es) | ||
| WO2002080859A3 (en) | Inhalation drug combinations | |
| MD4369B1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
| WO2006017505A2 (en) | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases | |
| BRPI0507544A (pt) | combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias | |
| JP2023532972A (ja) | グルココルチコイド節約剤 | |
| PE20050485A1 (es) | Nuevas sales de tiotropio, procedimiento para su preparacion, asi como formulaciones medicamentosas que las contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |